Tony Lakavage, USP, outlines pharma disruptions, pricing shifts, supply chain risks. As well as greening standards to build a resilient supply chain.
Tony Lakavage
Advertisement
Tony Lakavage, USP
Articles by Tony Lakavage
Tony Lakavage, executive vice president and head of Global External Affairs, US Pharmacopeia (USP), discusses how IRA negotiations, Most Favored Nation pricing, US manufacturing push, and new FDA biosimilar guidance are reshaping the industry.
Tony Lakavage, executive vice president and head of Global External Affairs, US Pharmacopeia (USP), discusses drug supply chain vulnerabilities tied to China dependence, urging resilience through mapping, nearshoring, and manufacturing reform.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Improving Oral Peptide Delivery Through Structural Modifications
2
Regulatory Roundup—October 2026: FDA Advances Rare Disease Development and Transparency Efforts
3
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
4
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
5